Tuesday, December 08, 2009 7:05:47 PM
R/S and dilution is the best way for a developmental biotech to get funding. The alternative is usually a loan at usurious rates.
I would welcome a 100:1 R/S to bring the pps to 30 cents. And increasing the authorized shares doesn't concern me either.
What concerns me is the suspicion that "ParaMax" is a figment of someone's imagination. If the company is on the verge of getting 510(k) clearance for a device, they must have submitted the application in August... so why no mention of ParaMax in the guidance that accompanied the last 10Q?
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM